UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer

Cancers, 2020-04, Vol.12 (4), p.989

2020

Volltextzugriff (PDF)

Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2

The Journal of biological chemistry, 2006-11, Vol.281 (44), p.33597-33605

2006

Volltextzugriff (PDF)

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Neutral endopeptidase is a myristoylated protein

Molecular and cellular biochemistry, 2010-02, Vol.335 (1-2), p.173-180

2010

Volltextzugriff (PDF)

The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells

Journal of cellular biochemistry, 2017-12, Vol.118 (12), p.4414-4424

2017

Volltextzugriff (PDF)

Urothelial Bladder Carcinoma With Choriocarcinomatous Differentiation Presenting With a False-Positive Pregnancy Test

The American journal of the medical sciences, 2013-09, Vol.346 (3), p.256-258

2013

Volltextzugriff (PDF)

Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter

Molecular and cellular endocrinology, 2006-10, Vol.259 (1), p.10-21

2006

Volltextzugriff (PDF)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Journal of medical case reports, 2009-09, Vol.3 (1), p.9110-9110

2009

Volltextzugriff (PDF)

Targeting DNA damage response to overcome taxane resistance

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.312-312

2018

Volltextzugriff (PDF)

Abstract B017: Role of CYP3A5 in modulating androgen receptor signaling and its relevance in African American prostate cancer patients

Cancer epidemiology, biomarkers & prevention, 2020-06, Vol.29 (6_Supplement_1), p.B017-B017

2020

Volltextzugriff (PDF)

Novel Antibody Approaches for T-Cell Lymphomas

Clinical lymphoma & myeloma, 2008-12, Vol.8, p.S193-S198

2008

Volltextzugriff (PDF)

Abstract 1311A: CYP3A5 regulation of androgen receptor signaling: Relevance in African American prostate cancer patients and its development as novel target

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1311-1311A

2019

Volltextzugriff (PDF)

Abstract B001: CYP3A5 promotes AR downstream signaling and contributes to therapeutic resistance

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.B001-B001

2018

Volltextzugriff (PDF)

Abstract 4650: Effect of prescription CYP3A inducers and inhibitors on response to anti-androgen therapy in prostate cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4650-4650

2016

Volltextzugriff (PDF)

Abstract B48: Effect of concomitant CYP3A5-modulating drugs on androgen-receptor signaling in African American men undergoing androgen deprivation therapy

Cancer epidemiology, biomarkers & prevention, 2018-07, Vol.27 (7_Supplement), p.B48-B48

2018

Volltextzugriff (PDF)

Abstract 3130: CYP3A5 positively regulates androgen receptor signaling in prostate cancer cells: Potential for therapeutic targeting

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3130-3130

2017

Volltextzugriff (PDF)

A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5097-TPS5097

2022

Volltextzugriff (PDF)

Mapping of the molecular determinants involved in the interaction between eps15 and AP-2

Cancer research (Chicago, Ill.), 1997-01, Vol.57 (2), p.240-245

1997

Volltextzugriff (PDF)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Journal of medical case reports, 2009-09, Vol.3 (1), p.9110-9110

2009

Volltextzugriff (PDF)

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Apalutamide plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, phase 3 study

The lancet oncology, 2021-09, Vol.22 (11), p.1541-1559

2021

Volltextzugriff (PDF)

Abstract 5414: RNA sequencing reveals that CYP3A5 siRNA treatment induces cell cycle blockade and senescence in MDAPCa2b human prostate cancer cells

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5414-5414

2022

Volltextzugriff (PDF)

Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.9-9

2021

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(14)
Humans
(10)
Oncology
(6)
Animals
(4)
Biochemistry & Molecular Biology
(4)
Molecular Sequence Data
(4)
Biochemistry
(3)
Biological Sciences
(3)
Cell Biology
(3)
Clathrin - Metabolism
(3)
General & Internal Medicine
(3)
Medicine, General & Internal
(3)
Multidisciplinary Sciences
(3)
Neprilysin - Metabolism
(3)
Science & Technology - Other Topics
(3)
Adaptor Proteins, Vesicular Transport
(2)
Adolescent
(2)
Adult
(2)
Amino Acid Sequence
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer

Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Neutral endopeptidase is a myristoylated protein

The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells

Urothelial Bladder Carcinoma With Choriocarcinomatous Differentiation Presenting With a False-Positive Pregnancy Test

Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Targeting DNA damage response to overcome taxane resistance

Abstract B017: Role of CYP3A5 in modulating androgen receptor signaling and its relevance in African American prostate cancer patients

Novel Antibody Approaches for T-Cell Lymphomas

Abstract 1311A: CYP3A5 regulation of androgen receptor signaling: Relevance in African American prostate cancer patients and its development as novel target

Abstract B001: CYP3A5 promotes AR downstream signaling and contributes to therapeutic resistance

Abstract 4650: Effect of prescription CYP3A inducers and inhibitors on response to anti-androgen therapy in prostate cancer

Abstract B48: Effect of concomitant CYP3A5-modulating drugs on androgen-receptor signaling in African American men undergoing androgen deprivation therapy

Abstract 3130: CYP3A5 positively regulates androgen receptor signaling in prostate cancer cells: Potential for therapeutic targeting

A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer

Mapping of the molecular determinants involved in the interaction between eps15 and AP-2

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP)

Apalutamide plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, phase 3 study

Abstract 5414: RNA sequencing reveals that CYP3A5 siRNA treatment induces cell cycle blockade and senescence in MDAPCa2b human prostate cancer cells

Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC)

Aktive Filter

Suchergebnisse filtern